Literature DB >> 11933217

High efficiency lentiviral gene delivery in non-dividing cells by deoxynucleoside treatment.

Elisabetta Ravot1, Giuditta Comolli, Franco Lori, Julianna Lisziewicz.   

Abstract

BACKGROUND: Gene therapy has recently been advanced by the development of HIV-based vectors that are able to transduce some non-dividing cells. The manipulation of most non-dividing cells remains, however, scarcely efficient. One of the biological mechanisms postulated to prevent powerful transduction of quiescent cells by lentiviral vectors is the paucity of deoxynucleotides (dNTPs). In this study, a novel delivery strategy is developed to improve significantly the efficiency of HIV-based vectors in transducing non-dividing cells. This approach is based on increasing the intracellular availability of dNTPs by incubating target cells with the dNTP precursors, deoxynucleosides (dNSs).
METHODS: Mature human monocyte-derived macrophages (14-21 days old) were transduced at a low multiplicity of infection (MOI) of HIV vectors carrying a reporter gene. dNSs were added to the medium during transduction (5 mM dNS) and immediately before post-transduction culture (2.5 mM dNS). Macrophages were harvested 2-7 days after transduction and assayed for transgene expression by cytofluorimetry.
RESULTS: The addition of dNS to the medium significantly enhanced the efficiency of transduction of human macrophages by HIV-based vectors. The percentage of cells expressing the transgene rose up to 50% in the presence of dNS, increasing the basal transduction levels up to 35-fold (average=10.8-fold). Furthermore, treatment with dNTP precursors compensated for the wide inter-donor variability, allowing the highest enhancement effects in donors with the lowest basal transduction efficiencies.
CONCLUSIONS: This is the first demonstration that a single treatment of non-dividing target cells with exogenous dNS can enhance the efficiency of lentiviral-mediated transduction of cells, allowing for high efficiency gene transfer. The effects of dNTP precursors compensated for both the poor basal levels and the wide inter-donor variability, two major limitations for the transduction of non-dividing cells. Macrophages are a representative model of cells whose permissiveness to gene delivery was increased up to levels suitable for genetic manipulation applications. This simple approach might be transferred to a broader range of quiescent cell types that are scarcely susceptible to lentiviral-based gene delivery due to low dNTP levels. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11933217     DOI: 10.1002/jgm.256

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  5 in total

1.  Characterization of the behavior of functional viral genomes during the early steps of human immunodeficiency virus type 1 infection.

Authors:  Vanessa Arfi; Julia Lienard; Xuan-Nhi Nguyen; Gregory Berger; Dominique Rigal; Jean-Luc Darlix; Andrea Cimarelli
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

Review 2.  Recent advances in lentiviral vector development and applications.

Authors:  Janka Mátrai; Marinee K L Chuah; Thierry VandenDriessche
Journal:  Mol Ther       Date:  2010-01-19       Impact factor: 11.454

3.  Restricting HIV the SAMHD1 way: through nucleotide starvation.

Authors:  Diana Ayinde; Nicoletta Casartelli; Olivier Schwartz
Journal:  Nat Rev Microbiol       Date:  2012-08-28       Impact factor: 60.633

4.  Collagen alpha1(I) gene (COL1A1) is repressed by RFX family.

Authors:  Pritam Sengupta; Yong Xu; Lin Wang; Russell Widom; Barbara D Smith
Journal:  J Biol Chem       Date:  2005-03-23       Impact factor: 5.157

5.  Evaluation of transduction efficiency in macrophage colony-stimulating factor differentiated human macrophages using HIV-1 based lentiviral vectors.

Authors:  Francisco J Leyva; Joshua J Anzinger; J Philip McCoy; Howard S Kruth
Journal:  BMC Biotechnol       Date:  2011-01-31       Impact factor: 2.563

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.